drugset / Trial / NCT06935266
A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults
RandomizedParallel-groupOpen-labelOther
Summary
The main aim of this study is to check how well healthy adults can tolerate TAK-881 with different dosing schedules. During the study, participants will receive one infusion of TAK-881 under the skin (subcutaneous \[SC\] infusion) on Day 1 at a lower dose level followed by participants receiving multiple infusion of higher dose levels. Participants will be in the study for approximately 19 weeks including screening period and follow-up (End of Treatment \[EOT\]).
Timeline
- Start
- 2025-04-22
- Primary completion
- 2025-09-22
- Completion
- 2025-09-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Immune Globulin Intravenous (Human) | Protein / enzyme biologic | 0.6 g/kg | Subcutaneous |
| Subject | Immune Globulin Intravenous (Human) | Protein / enzyme biologic | 1 g/kg | Subcutaneous |
| Subject | Immune Globulin Intravenous (Human) | Protein / enzyme biologic | 2 g/kg | Subcutaneous |
Indications
No indication recorded.